S&P 500   5,107.42 (+0.22%)
DOW   38,984.10 (-0.03%)
QQQ   441.83 (+0.64%)
AAPL   178.68 (-1.15%)
MSFT   412.41 (-0.30%)
META   500.47 (+2.11%)
GOOGL   137.71 (-0.54%)
AMZN   177.03 (+0.15%)
TSLA   199.90 (-0.98%)
NVDA   807.88 (+2.12%)
NIO   5.75 (+0.00%)
AMD   200.15 (+3.96%)
BABA   74.55 (+0.70%)
T   17.00 (+0.41%)
F   12.62 (+1.45%)
MU   95.09 (+4.94%)
CGC   3.17 (-3.65%)
GE   158.49 (+1.02%)
DIS   111.89 (+0.28%)
AMC   4.36 (+0.93%)
PFE   26.61 (+0.19%)
PYPL   61.63 (+2.14%)
XOM   105.80 (+1.22%)
S&P 500   5,107.42 (+0.22%)
DOW   38,984.10 (-0.03%)
QQQ   441.83 (+0.64%)
AAPL   178.68 (-1.15%)
MSFT   412.41 (-0.30%)
META   500.47 (+2.11%)
GOOGL   137.71 (-0.54%)
AMZN   177.03 (+0.15%)
TSLA   199.90 (-0.98%)
NVDA   807.88 (+2.12%)
NIO   5.75 (+0.00%)
AMD   200.15 (+3.96%)
BABA   74.55 (+0.70%)
T   17.00 (+0.41%)
F   12.62 (+1.45%)
MU   95.09 (+4.94%)
CGC   3.17 (-3.65%)
GE   158.49 (+1.02%)
DIS   111.89 (+0.28%)
AMC   4.36 (+0.93%)
PFE   26.61 (+0.19%)
PYPL   61.63 (+2.14%)
XOM   105.80 (+1.22%)
S&P 500   5,107.42 (+0.22%)
DOW   38,984.10 (-0.03%)
QQQ   441.83 (+0.64%)
AAPL   178.68 (-1.15%)
MSFT   412.41 (-0.30%)
META   500.47 (+2.11%)
GOOGL   137.71 (-0.54%)
AMZN   177.03 (+0.15%)
TSLA   199.90 (-0.98%)
NVDA   807.88 (+2.12%)
NIO   5.75 (+0.00%)
AMD   200.15 (+3.96%)
BABA   74.55 (+0.70%)
T   17.00 (+0.41%)
F   12.62 (+1.45%)
MU   95.09 (+4.94%)
CGC   3.17 (-3.65%)
GE   158.49 (+1.02%)
DIS   111.89 (+0.28%)
AMC   4.36 (+0.93%)
PFE   26.61 (+0.19%)
PYPL   61.63 (+2.14%)
XOM   105.80 (+1.22%)
S&P 500   5,107.42 (+0.22%)
DOW   38,984.10 (-0.03%)
QQQ   441.83 (+0.64%)
AAPL   178.68 (-1.15%)
MSFT   412.41 (-0.30%)
META   500.47 (+2.11%)
GOOGL   137.71 (-0.54%)
AMZN   177.03 (+0.15%)
TSLA   199.90 (-0.98%)
NVDA   807.88 (+2.12%)
NIO   5.75 (+0.00%)
AMD   200.15 (+3.96%)
BABA   74.55 (+0.70%)
T   17.00 (+0.41%)
F   12.62 (+1.45%)
MU   95.09 (+4.94%)
CGC   3.17 (-3.65%)
GE   158.49 (+1.02%)
DIS   111.89 (+0.28%)
AMC   4.36 (+0.93%)
PFE   26.61 (+0.19%)
PYPL   61.63 (+2.14%)
XOM   105.80 (+1.22%)
NASDAQ:APTX

Aptinyx (APTX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$0.09
$0.10
50-Day Range
$0.06
$0.10
52-Week Range
$0.01
$0.72
Volume
231,100 shs
Average Volume
1.32 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

APTX stock logo

About Aptinyx Stock (NASDAQ:APTX)

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.


APTX Stock News Headlines

Patrick J Heron's Net Worth
Best Noise-Canceling Headphones for 2024
Bezos and Gates Invest in Search for Tech's Best-Kept Secret
Billionaires who've made their fortunes in tech, are quietly investing in essential yet rare elements known as "The Seeds of Technology". Learn more about this massive rare earth treasure hunt and the very elements making emerging technologies possible.
Aptinyx Inc APTX
North American Morning Briefing: Concerns About -2-
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Aptinyx (NASDAQ: APTX)
H.C. Wainwright Keeps Their Buy Rating on Aptinyx (APTX)
Aptinyx Inc. (NASDAQ: APTX)
Aptinyx Inc. (APTX)
What 4 Analyst Ratings Have To Say About Aptinyx
See More Headlines
Receive APTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptinyx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
3/01/2024
Next Earnings (Estimated)
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:APTX
Fax
N/A
Employees
12
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1 million
Book Value
$0.57 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
1.27
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for March 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Craig R. Jalbert CIRA (Age 61)
    Principal Executive Officer, Fin. & Accounting Officer, President, Treasurer, Secretary and Director
  • Mr. Patrick Flavin
    Senior Manager of Corporate Development & Investor Relations
  • Ms. Molly Dir
    Vice President of Human Resources
  • Dr. Kathryn King Ph.D.
    Senior Vice President of Clinical & CMC Operations
  • Mr. Tim Noffke
    VP of Program Management & Chief of Staff
  • Dr. Harald Murck M.D.
    Ph.D., Vice President of Clinical & Medical Affairs














APTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Aptinyx stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aptinyx in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" APTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in APTX, but not buy additional shares or sell existing shares.
View APTX analyst ratings
or view top-rated stocks.

When is Aptinyx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our APTX earnings forecast
.

How were Aptinyx's earnings last quarter?

Aptinyx Inc. (NASDAQ:APTX) posted its quarterly earnings data on Tuesday, November, 9th. The company reported ($0.31) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.31). During the same quarter in the prior year, the firm earned ($0.24) EPS.

What other stocks do shareholders of Aptinyx own?
When did Aptinyx IPO?

(APTX) raised $77 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 5,300,000 shares at $14.00-$15.00 per share. J.P. Morgan, Cowen, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

This page (NASDAQ:APTX) was last updated on 3/1/2024 by MarketBeat.com Staff